1st Quarter 2022

1st Quarter 2022


In January 2022, the first Convention of HEMERA members was held in Desenzano del Garda (VR). Over 50 members from all over Italy attended the event, an opportunity to meet and exchange ideas among the participants, including collaborators, partners, and guests interested in the company’s growth prospects.

The day’s program included several interventions that allowed the participants to get to know Hemera, the research team, the therapy, and its developments in depth:

Corrado Creston, Add Value CEO and Hemera First investor

Guido Fumagalli, Hemera’s President
The story of the project

Massimo Locati, Scientific Director
TEM therapy invention

Ilaria Decimo, R&D Director
Hemera’s research and development

Francesco Bifari, Direttore Sviluppo ClinicoDirector of clinical development
The clinical experimentation

Marco Riva, Ricercatore Humanitas University Researcher
Spinal cord lesion treatment: present and future

Cristiana Vignoli, CEO
Action Plan & Milestones


In February 2022, the following brands have been registered at the Italian Patent and Trademark Office – UIBM:

Hemera’s corporate brand

the brand TEM (acronym for Tumor Educated Macrophages)

the brand THEM (acronym for Tumor and Hypoxia Educated Macrophages)


The international patent application was filed according to the PCT protocol – Patent Cooperation Treaty in all participating countries worldwide.

The PCT protocol ensures patent protection for the invention of TEM therapy in over 150 countries.


In March 2022, the 4th capital increase since Hemera’s foundation, equivalent to € 630,000, was formalized.

Up to date Hemera collected investments totaling €1,410,000 from 102 investors.

The fundraising campaign continues, next round will end on June 30, 2022.